2557 Platinum-based therapy in heavily pretreated m CRPC patients

Evangelos Bournakis; E. Kostouros; Nikolaos Soupos; Meletios A Dimopoulos; C. Papadimitriou

doi:10.1016/s0959-8049(16)31376-4

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Preprint2021

Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer

Αngeliki Andrikopoulou, Michalis Liontos, Efthymia Skafida, Konstantinos Koutsoukos, Kleoniki Apostolidou, Μαρία Καπαρέλου, Angeliki Rouvalis, Garyfallia Bletsa, Meletios A Dimopoulos, Flora Zagouri

Article2022

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Meletios A Dimopoulos, Paul G. Richardson, Sagar Lonial

Article2022

DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Meletios A Dimopoulos, Paul G. Richardson, Sagar Lonial

Article2003

Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer

Gerasimos Aravantinos, Dimitrios Bafaloukos, George Fountzilas, Christos Christodoulou, Christos Papadimitriou, N Pavlidis, Haralabos P. Kalofonos, Helen Gogas, P. Kosmidis, Meletios A Dimopoulos

Article2023

Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer

Αngeliki Andrikopoulou, Michalis Liontos, Efthymia Skafida, Konstantinos Koutsoukos, Kleoniki Apostolidou, Maria Kaparelou, Angeliki Rouvalis, Garyfallia Bletsa, Meletios A Dimopoulos, Flora Zagouri